Turalio (pexidartinib capsules – Daiichi Sankyo) — Cigna
Histiocytic Neoplasms (Langerhans cell histiocytosis, Erdheim-Chester disease, Rosai-Dorfman disease)
Initial criteria
- Patient is age ≥ 18 years
- Patient has a colony stimulating factor 1 receptor (CSF1R) mutation
- Patient has ONE of the following: Langerhans cell histiocytosis OR Erdheim-Chester disease OR Rosai-Dorfman disease
Approval duration
1 year